Skip to main content

Advertisement

SpringerLink
Log in

Status and thoughts of Chinese patent medicines seeking approval in the US market

  • Feature Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Veregen™ and Fulyzaq are the first two botanical drug products that were approved by the Food and Drug Administration (FDA) to market in the US in recent years. Additional herbal medicines, including Compound Danshen Dripping Pills (复方丹参滴丸), Fuzheng Huayu Tablets (扶正化瘀片), Xuezhikang Capsule (血 脂康胶囊), Guizhi Fuling Capsule (桂枝茯苓胶囊), Kanglaite Capsule (康莱特胶囊) and Kanglaite Injection (康莱特注射液), have filed the investigational new drug (IND) application to the FDA and are in phase II or phase III clinical development. In order to gain better understanding of the process of botanical drug approval in the US, this article examines the aforementioned drugs by looking at their composition, indication, prior clinical experience and clinical development process, and summarizes key features that enabled IND filing and marketing approval by the FDA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gan SJ, Li ZJ, Zou JQ, Xu YL, Jia Q, Hong J, et al. TCM modernization development strategy. Bullet Med Res (Chin) 2000;29:22–23.

    Google Scholar 

  2. Department of Health and Human Services, Food and Drug Administration, US. Guidance for industry botanical drug products (EB/OL). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070491.pdf.

  3. Zhou H. The first American herbal medicine Veregen™’s introduction and enlightenment of Chinese medicine research and development. Tradit Chin Drug Res Clin Pharmacol (Chin) 2008;19:326–328.

    Google Scholar 

  4. Zhang ZJ, Chen YF, Ye ZL, Zhang XN, Dong HO. Information and enlightenment on the first oral botanical drug Fulyzaq approved by FDA. Drugs Clin (Chin) 2013;28:421–423.

    Google Scholar 

  5. ClinicalTrials.gov. Phase II multi-center study of T89 to treat chronic stable angina (T89 Phase 2). http://clinicaltrials.gov/ct2/show/NCT00797953?term=Dantonic&rank=5.

  6. ClinicalTrials.gov. Phase III trial of Dantonic® (T89) Capsule to prevent and treat stable angina (CAESA). http://clinicaltrials.gov/show/NCT01659580.

  7. ClinicalTrials.gov. Treatment of primary menstrual pain with Kanion Capsule. http://clinicaltrials.gov/ct2/show/NCT01659580?term=Dantonic&rank=2.

  8. ClinicalTrials.gov. Effect of KYG0395 on primary dysmenorrhea. http://clinicaltrials.gov/ct2/show/NCT01588236?term=KYG0395&rank=1.

  9. ClinicalTrials.gov. Assess the anti-fibrotic activity of Fuzheng huayu in chronic hepatitis C patients with hepatic fibrosis. http://clinicaltrials.gov/ct2/show/NCT00854087?term=NCT00854087&rank=1.

  10. ClinicalTrials.gov. Efficacy and safety study of lipidlowering effects of XueZhiKang (XZK) in patients with hyperlipidemia. http://clinicaltrials.gov/ct2/show/NCT01327014?term=XueZhiKang&rank=2.

  11. ClinicalTrials.gov. Safety and efficacy of Kanglaite Gelcaps in prostate cancer. http://clinicaltrials.gov/ct2/show/NCT01483586?term=Kanglaite+Gelcaps&rank=1.

  12. ClinicalTrials.gov. Safety and exploratory efficacy of Kanglaite Injection in pancreatic cancer. http://clinicaltrials.gov/ct2/show/NCT00733850?term=Kanglaite+Injection&rank=2.

  13. ClinicalTrials.gov. Phase II Study of HMPL-004 in Patients With Ulcerative Colitis. http://clinicaltrials.gov/ct2/show/NCT00659802?term=HMPL004&rank=4.

  14. ClinicalTrials.gov. A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis. http://clinicaltrials.gov/ct2/show/NCT01805791?term=HMPL004&rank=2.

  15. ClinicalTrials.gov. Phase II Study of HMPL-004 in Subjects With Crohn’s Disease. http://clinicaltrials.gov/ct2/show/NCT00655733?term=HMPL-004&rank=1.

  16. FDA. Review classification policy: priority (P) and standard (S). http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/ucm082000.pdf.

  17. Liu CH, Bian HS, Wen JP. Introduction of Fuzheng Huayu Tablets anti-fibrosis in chronic hepatitis C the United States clinical trials. Drug Eval (Chin) 2008;5:201–203.

    Google Scholar 

  18. Xin YW, Li HL, Chen GL. New drugs approved by FDA in 2012. Chin J New Drugs (Chin) 2013;22:863–868.

    Google Scholar 

  19. BIOONNEWS. The FDA Phase II clinical trials of Guizhi Fuling Capsule have a good starting. http://www.bioon.com/industry/china/363219.shtml.

  20. Zhao LB, He Y, Guo ZX, Sun H. New prospect on research and development of Chinese materia medica and phytomedicines in global. Drug Eval Res (Chin) 2011;34:1–7.

    Google Scholar 

  21. Guo HP. FDA approved CSDP entering clinical trials directly. Spec J Pharm People Mil Surg (Chin) 1998;14:26.

    Google Scholar 

  22. Duan ZW, Guo SR, Liu PL. The process of internationalization of Xuezhikang Capsule. 2011 China Pharmaceutical Conference and the 11th China Proceedings of Pharmacist, Yantai; 2011:1–2.

    Google Scholar 

  23. The newsletter of Fuzheng Huayu Tablets in American II clinical trials. Chin J Integr Tradit West Med Liver Dis (Chin) 2010;20:199.

  24. Chen SC, Dou JH. Overview on guidance for industry: botanical drug products of FDA and approval of botanical drug products. China Prescription Drug (Chin) 2008;77:44–46.

    Google Scholar 

  25. Zhang XD, Li LD. Consideration about current non-clinical safety evaluation of Chinese material medica and natural drug from FDA’s botanical drug registration cases. Chin J New Drugs Clin Rem (Chin) 2010;29:251–255.

    CAS  Google Scholar 

  26. Wang GB, Cao J, Ma XH, Li ZW, Luo RZ, Guo ZX, et al. Requirements of FDA for preclinical toxicological studies on preparation of phytomedicine in US. Chin Tradit Herbal Drugs (Chin) 2013;44:116–119.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

    Xiang Lei  (雷 翔), Jing Chen  (陈 静), Chun-Xiang Liu  (刘春香), Jia Lin  (林 佳), Jing Lou  (楼 静) & Hong-cai Shang  (商洪才)

  2. Tianjin Institute of Clinical Evaluation of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

    Xiang Lei  (雷 翔), Chun-Xiang Liu  (刘春香), Jia Lin  (林 佳), Jing Lou  (楼 静) & Hong-cai Shang  (商洪才)

Authors
  1. Xiang Lei  (雷 翔)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Chen  (陈 静)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chun-Xiang Liu  (刘春香)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia Lin  (林 佳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Lou  (楼 静)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong-cai Shang  (商洪才)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong-cai Shang  (商洪才).

Additional information

Supported by Natural Science Foundation of China (No. 81273935)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lei, X., Chen, J., Liu, CX. et al. Status and thoughts of Chinese patent medicines seeking approval in the US market. Chin. J. Integr. Med. 20, 403–408 (2014). https://doi.org/10.1007/s11655-014-1936-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-014-1936-0

Keywords

Search

Navigation